Exscientia (EXAI) Competitors $5.01 +0.11 (+2.24%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends EXAI vs. RLAY, ABCL, SDGR, RXRX, LBPH, SRRK, SWTX, KROS, AKRO, and VCELShould you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Schrödinger (SDGR), Recursion Pharmaceuticals (RXRX), Longboard Pharmaceuticals (LBPH), Scholar Rock (SRRK), SpringWorks Therapeutics (SWTX), Keros Therapeutics (KROS), Akero Therapeutics (AKRO), and Vericel (VCEL). These companies are all part of the "medical" sector. Exscientia vs. Relay Therapeutics AbCellera Biologics Schrödinger Recursion Pharmaceuticals Longboard Pharmaceuticals Scholar Rock SpringWorks Therapeutics Keros Therapeutics Akero Therapeutics Vericel Relay Therapeutics (NASDAQ:RLAY) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings. Does the media favor RLAY or EXAI? In the previous week, Relay Therapeutics had 6 more articles in the media than Exscientia. MarketBeat recorded 6 mentions for Relay Therapeutics and 0 mentions for Exscientia. Relay Therapeutics' average media sentiment score of 0.06 beat Exscientia's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relay Therapeutics Neutral Exscientia Neutral Does the MarketBeat Community prefer RLAY or EXAI? Relay Therapeutics received 43 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 67.50% of users gave Relay Therapeutics an outperform vote while only 37.93% of users gave Exscientia an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes5467.50% Underperform Votes2632.50% ExscientiaOutperform Votes1137.93% Underperform Votes1862.07% Which has preferable earnings & valuation, RLAY or EXAI? Exscientia has lower revenue, but higher earnings than Relay Therapeutics. Exscientia is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$25.55M30.66-$341.97M-$2.52-2.32Exscientia$21.02M28.81-$181.56M-$1.30-3.85 Is RLAY or EXAI more profitable? Relay Therapeutics has a net margin of 0.00% compared to Exscientia's net margin of -620.99%. Exscientia's return on equity of -37.56% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -43.66% -38.38% Exscientia -620.99%-37.56%-26.19% Which has more risk and volatility, RLAY or EXAI? Relay Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Do insiders & institutionals have more ownership in RLAY or EXAI? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 41.6% of Exscientia shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 16.4% of Exscientia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend RLAY or EXAI? Relay Therapeutics currently has a consensus price target of $21.11, suggesting a potential upside of 260.87%. Exscientia has a consensus price target of $7.00, suggesting a potential upside of 39.72%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Relay Therapeutics is more favorable than Exscientia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Exscientia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryRelay Therapeutics beats Exscientia on 13 of the 18 factors compared between the two stocks. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get Exscientia News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAI vs. The Competition Export to ExcelMetricExscientiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$605.64M$3.11B$5.04B$8.43BDividend YieldN/A1.76%7.52%4.16%P/E Ratio-3.8516.06130.7816.68Price / Sales28.81311.891,683.1176.29Price / CashN/A144.3536.9133.54Price / Book1.373.974.604.98Net Income-$181.56M-$42.08M$115.00M$224.39M7 Day Performance-4.21%-0.85%-0.26%1.30%1 Month Performance8.91%8.29%5.73%4.90%1 Year Performance-13.77%28.28%33.72%26.31% Exscientia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXAIExscientia1.3124 of 5 stars$5.01+2.2%$7.00+39.7%-13.8%$592.34M$25.60M-3.85280RLAYRelay Therapeutics3.3298 of 5 stars$5.84+3.5%$21.11+261.5%-22.2%$781.92M$25.55M-2.32304Upcoming EarningsABCLAbCellera Biologics1.9687 of 5 stars$2.73flat$10.33+278.5%-38.5%$804.45M$38.03M-5.06586News CoverageSDGRSchrödinger2.0446 of 5 stars$17.99+2.3%$32.60+81.2%-35.6%$1.31B$216.67M-6.71867Upcoming EarningsRXRXRecursion Pharmaceuticals2.8636 of 5 stars$6.40+1.3%$9.40+46.9%+12.4%$1.80B$48.62M-3.95400Upcoming EarningsLBPHLongboard Pharmaceuticals1.7144 of 5 stars$59.69-0.1%$59.56-0.2%+977.9%$2.32BN/A-27.7620Upcoming EarningsSRRKScholar Rock4.6275 of 5 stars$28.42-0.1%$33.29+17.1%+123.0%$2.27B$33.19M-12.80140Upcoming EarningsAnalyst ForecastSWTXSpringWorks Therapeutics1.391 of 5 stars$30.62+1.6%$68.50+123.7%+27.3%$2.27B$5.45M-6.91305Upcoming EarningsNews CoveragePositive NewsKROSKeros Therapeutics3.4375 of 5 stars$59.94+3.3%$89.11+48.7%+87.7%$2.25B$150,000.00-11.68100Positive NewsAKROAkero Therapeutics3.878 of 5 stars$32.33+4.9%$43.20+33.6%+119.8%$2.24BN/A-9.4830Upcoming EarningsPositive NewsVCELVericel2.6896 of 5 stars$43.99-0.1%$57.71+31.2%+20.4%$2.16B$197.52M-4,399,000.00300Upcoming EarningsPositive News Related Companies and Tools Related Companies Relay Therapeutics Competitors AbCellera Biologics Competitors Schrödinger Competitors Recursion Pharmaceuticals Competitors Longboard Pharmaceuticals Competitors Scholar Rock Competitors SpringWorks Therapeutics Competitors Keros Therapeutics Competitors Akero Therapeutics Competitors Vericel Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EXAI) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXAI Stock Alerts